A 2026 partnering scan of Acurx Pharmaceuticals, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Activartis Biotech GmbH, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Invivyd, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Actym Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Adimmune Corp., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Accent Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Abpro Corp., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Actinogen Medical Ltd., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Acorda Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Actinium Pharmaceuticals, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of AavantiBio, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of AAVantgarde Bio Srl, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.